IOVANCE BIOTHERAPEUTICS, INC. Operating Lease Cost
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Operating Lease Cost of $1.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-06-30 was $1.77M, a 54.80% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-03-31 was $2.77M, a 30.07% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-12-31 was $3.69M, a 18.97% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-09-30 was $3.94M, a 4.95% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, cost for fiscal 2025 was $15.52M, a 5.87% decline from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, cost for fiscal 2024 was $16.48M, a 7.32% decline from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, cost for fiscal 2023 was $17.79M, a 0.73% increase from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. operating lease, cost for fiscal 2022 was $17.66M, a 15.10% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.77M 10-Q · filed 2026-08-06 | $4.55M 10-Q · filed 2026-08-06 | $8.23M derived: sum of 3 quarters · filed 2026-08-06 | $12.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.77M 10-Q · filed 2026-05-07 | $6.46M derived: sum of 2 quarters · filed 2026-05-07 | $10.40M derived: sum of 3 quarters · filed 2026-05-07 | $14.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.62M derived: sum of 2 quarters · filed 2026-02-24 | $11.55M derived: sum of 3 quarters · filed 2026-08-06 | $15.52M 10-K · filed 2026-02-24 |
| 2025-09-30 | $3.94M 10-Q · filed 2025-11-06 | $7.86M derived: sum of 2 quarters · filed 2026-08-06 | $11.83M 10-Q · filed 2025-11-06 | $16.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.92M 10-Q · filed 2026-08-06 | $7.89M 10-Q · filed 2026-08-06 | $12.44M derived: sum of 3 quarters · filed 2026-08-06 | $16.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.97M 10-Q · filed 2026-05-07 | $8.52M derived: sum of 2 quarters · filed 2026-05-07 | $12.66M derived: sum of 3 quarters · filed 2026-05-07 | $16.65M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $8.69M derived: sum of 2 quarters · filed 2026-02-24 | $12.69M derived: sum of 3 quarters · filed 2026-02-24 | $16.48M 10-K · filed 2026-02-24 |
| 2024-09-30 | $4.14M 10-Q · filed 2025-11-06 | $8.14M derived: sum of 2 quarters · filed 2025-11-06 | $11.93M 10-Q · filed 2025-11-06 | $16.24M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $4.00M 10-Q · filed 2025-08-07 | $7.79M 10-Q · filed 2025-08-07 | $12.10M derived: sum of 3 quarters · filed 2025-08-07 | $16.54M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $3.80M 10-Q · filed 2025-05-08 | $8.10M derived: sum of 2 quarters · filed 2025-05-08 | $12.54M derived: sum of 3 quarters · filed 2025-05-08 | $17.06M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $8.74M derived: sum of 2 quarters · filed 2025-02-27 | $13.26M derived: sum of 3 quarters · filed 2025-02-27 | $17.79M 10-K · filed 2025-02-27 |
| 2023-09-30 | $4.44M 10-Q · filed 2024-11-07 | $8.96M derived: sum of 2 quarters · filed 2024-11-07 | $13.48M 10-Q · filed 2024-11-07 | $18.02M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $4.52M 10-Q · filed 2024-08-08 | $9.04M 10-Q · filed 2024-08-08 | $13.58M derived: sum of 3 quarters · filed 2024-08-08 | $17.75M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.52M 10-Q · filed 2024-05-09 | $9.06M derived: sum of 2 quarters · filed 2024-05-09 | $13.23M derived: sum of 3 quarters · filed 2024-05-09 | $17.63M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $8.70M derived: sum of 2 quarters · filed 2024-02-28 | $13.10M derived: sum of 3 quarters · filed 2024-02-28 | $17.66M 10-K · filed 2024-02-28 |
| 2022-09-30 | $4.17M 10-Q · filed 2023-11-07 | $8.57M derived: sum of 2 quarters · filed 2023-11-07 | $13.12M 10-Q · filed 2023-11-07 | $17.63M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $4.40M 10-Q · filed 2023-08-08 | $8.95M 10-Q · filed 2023-08-08 | $13.46M derived: sum of 3 quarters · filed 2023-08-08 | $17.52M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $4.55M 10-Q · filed 2023-05-10 | $9.06M derived: sum of 2 quarters · filed 2023-05-10 | $13.12M derived: sum of 3 quarters · filed 2023-05-10 | $16.50M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $8.56M derived: sum of 2 quarters · filed 2023-02-28 | $11.94M derived: sum of 3 quarters · filed 2023-02-28 | $15.34M 10-K · filed 2023-02-28 |
| 2021-09-30 | $4.05M 10-Q · filed 2022-11-03 | $7.43M derived: sum of 2 quarters · filed 2022-11-03 | $10.83M 10-Q · filed 2022-11-03 | $14.20M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $3.38M 10-Q · filed 2022-08-04 | $6.78M 10-Q · filed 2022-08-04 | $10.14M derived: sum of 3 quarters · filed 2022-08-04 | $11.80M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $3.40M 10-Q · filed 2022-05-05 | $6.76M derived: sum of 2 quarters · filed 2022-05-05 | $8.42M derived: sum of 3 quarters · filed 2022-05-05 | $10.49M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $5.02M derived: sum of 2 quarters · filed 2022-02-24 | $7.09M derived: sum of 3 quarters · filed 2022-02-24 | $8.73M 10-K · filed 2022-02-24 |
| 2020-09-30 | $1.65M 10-Q · filed 2021-11-04 | $3.73M derived: sum of 2 quarters · filed 2021-11-04 | $5.36M 10-Q · filed 2021-11-04 | $9.09M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $2.07M 10-Q · filed 2021-08-05 | $3.71M 10-Q · filed 2021-08-05 | $7.43M derived: sum of 3 quarters · filed 2021-08-05 | $9.65M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $1.64M 10-Q · filed 2021-05-06 | $5.36M derived: sum of 2 quarters · filed 2021-05-06 | $7.57M derived: sum of 3 quarters · filed 2021-05-06 | $9.26M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $5.94M derived: sum of 2 quarters · filed 2021-02-25 | $7.62M derived: sum of 3 quarters · filed 2021-02-25 | $9.21M 10-K · filed 2021-02-25 |
| 2019-09-30 | $2.21M 10-Q · filed 2020-11-05 | $3.90M derived: sum of 2 quarters · filed 2020-11-05 | $5.49M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $1.68M 10-Q · filed 2020-08-06 | $3.27M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $1.59M 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |